HC Wainwright Reaffirms Neutral Rating for Trillium Therapeutics (TSE:TR)

HC Wainwright reaffirmed their neutral rating on shares of Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) in a research report report published on Monday morning, Zacks.com reports.

Trillium Therapeutics has a 1-year low of C$28.50 and a 1-year high of C$39.45.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).

Featured Story: What are no-load funds?

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.